NanoViricides (NYSEMKT:NNVC) is, again, leading coronavirus outbreak-related tickers premarket. Shares are up 38% on average volume after it confirmed that it is working on a treatment for 2019-nCoV, also known as the Wuhan coronavirus.
President & Executive Chairman Anil Diwan,
Ph.D. stated that the company has initiated a program but it will need
support from governmental and international agencies such as the US CDC,
WHO, and Chinese CDC but has not been contacted as yet.
2019-nCov is closely related to SARS-CoV which
caused the outbreak in 2002-2003, with the same cell surface receptor,
ACE2. According to Dr. Diwan, they have already identified some
candidate ligands in their chemical library that can bind to the
SARS-CoV spike protein in the same way as ACE2.
Related tickers and premarket movement: Allied Healthcare Products (NASDAQ:AHPI) (+7%), Novavax (NASDAQ:NVAX) (+2%), Alpha Pro Tech (NYSEMKT:APT) (+6%), Co-Diagnostics (NASDAQ:CODX) (+11%), Cleveland BioLabs (NASDAQ:CBLI) (+10%), Inovio Pharmaceuticals (NASDAQ:INO) (+1%)
https://seekingalpha.com/news/3536746-nanoviricides-up-38-after-confirming-work-on-coronavirus-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.